Edition:
United States

Rockwell Medical Inc (RMTI.OQ)

RMTI.OQ on NASDAQ Stock Exchange Global Market

8.09USD
21 Apr 2017
Change (% chg)

$-0.33 (-3.92%)
Prev Close
$8.42
Open
$8.57
Day's High
$8.65
Day's Low
$7.64
Volume
262,542
Avg. Vol
82,818
52-wk High
$10.56
52-wk Low
$3.55

Latest Key Developments (Source: Significant Developments)

Rockwell Medical Q4 loss per share $0.10
Wednesday, 15 Mar 2017 04:01pm EDT 

Rockwell Medical Inc : Rockwell medical reports fourth quarter results . Q4 loss per share $0.10 . Qtrly sales were $13.4 million, or $0.7 million lower than q4 2015 . "have advanced our clinical development work for triferic in both china and india markets" .Q4 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S.  Full Article

Richmond Brothers and Mark Ravich respond to Rockwell Medical lawsuit
Thursday, 9 Mar 2017 09:00am EST 

Rockwell Medical Inc : Richmond Brothers Inc and Mark Ravich respond to Rockwell Medical Inc Lawsuit .Richmond Brothers, Inc - "Believe Rockwell's allegations are baseless and untrue".  Full Article

David Richmond reports 10.8 pct stake in Rockwell Medical
Tuesday, 21 Feb 2017 09:13am EST 

Rockwell Medical Inc : David Richmond reports 10.8 percent stake in Rockwell Medical Inc as of Feb 20 - sec filing . David Richmond - purchased Rockwell Medical Inc's shares based on belief that shares, when purchased, were undervalued . David Richmond-believe that Rockwell Medical remains significantly undervalued in large part due to poor corporate governance practices,operational missteps by management team,board .David richmond-intend to engage in discussions with rockwell medical's management, board, stockholders,other interested parties regarding capital allocation,strategic plans.  Full Article

Rockwell Medical updates progress on Calcitriol commercial launch
Tuesday, 21 Feb 2017 09:00am EST 

Rockwell Medical Inc : Rockwell Medical updates progress on calcitriol commercial launch . Rockwell Medical Inc - FDA has requested that company resubmit application for new contract manufacturer as a prior approval supplement . Rockwell Medical Inc - FDA has requested that company pay a fee for agency review .Rockwell Medical Inc - company anticipates calcitriol to become commercially available in u.s. Market in approximately 4-6 months.  Full Article

Rockwell Medical reports Q3 loss per share $0.09
Monday, 7 Nov 2016 04:01pm EST 

Rockwell Medical Inc : Rockwell Medical reports third quarter results .Q3 loss per share $0.09.  Full Article

Rockwell Medical enters into license agreement with ARAM Medical
Tuesday, 16 Aug 2016 08:00am EDT 

Rockwell Medical Inc: Rockwell Medical enters into exclusive license agreement with ARAM Medical to commercialize Triferic® in Saudi Arabia, Egypt and Middle East territories . ARAM will also assume responsibility for all clinical and regulatory expenses for territories . Rockwell retains manufacturing responsibilities for both Triferic and Calcitriol . Commercial product availability expected within about 12 months in Saudi Arabia and 12 to 18 months in Egypt and all other territories . ARAM medical will become exclusive distributor for Triferic and Calcitriol in 13 countries .ARAM will pay to Rockwell upfront licensing fees, a "high double-digit royalty on product sales".  Full Article

Rockwell Medical Inc - qtrly sales were $13.5 mln, or 3.8% higher than Q2 2015
Monday, 8 Aug 2016 04:01pm EDT 

Rockwell Medical Inc :Qtrly sales were $13.5 million, or 3.8% higher than q2 2015..  Full Article

Rockwell Medical Q1 loss per share $0.10
Tuesday, 10 May 2016 04:01pm EDT 

Rockwell Medical Inc : Rockwell Medical reports first quarter results . Qtrly net loss $0.10 per share . Q1 earnings per share view $-0.08, revenue view $15.2 million -- Thomson Reuters I/B/E/S . Q1 loss per share $0.10 .Q1 sales $13.6 million versus $13.9 million.  Full Article

Rockwell Medical enters into license agreement with Wanbang Biopharmaceutical Co., Ltd. to commercialize Triferic® in China
Tuesday, 16 Feb 2016 08:00am EST 

Rockwell Medical Inc:Rockwell Medical enters into exclusive license agreement with wanbang biopharmaceutical co., ltd. to commercialize triferic® in China.Wanbang will become the exclusive distributor for triferic and calcitriol in China for an initial commercial term of 10 years.Agreements with wanbang biopharmaceutical for rights to commercialize triferic and calcitriol for end-stage-renal-disease patients.Will receive from wanbang an upfront fee plus regulatory and revenue milestone payments totaling USD$39 million in aggregate.Rockwell will receive ongoing earnings from product sales of triferic,calcitriol, other additional triferic therapeutic indications.  Full Article

Rockwell Medical announces Triferic phase 3 cruise studies published in nephrology dialysis transplantation
Wednesday, 15 Jul 2015 08:00am EDT 

Rockwell Medical Inc:Announces Triferic phase 3 cruise studies published in nephrology dialysis transplantation.Says both studies successfully met the primary endpoint.Says no serious adverse events or deaths were attributed to triferic.  Full Article

More From Around the Web

BRIEF-Richmond Bros. and Mark H. Ravich send letter to Rockwell Medical Shareholders

* Richmond Brothers and Mark H. Ravich send letter to Rockwell Medical Inc Shareholders Source text for Eikon: Further company coverage: